Lowest Price Guaranteed
Pages
33
Last Updated
December 2025
View Count
17116
Global expenditure on veterinary healthcare has been on the rise, driven by various factors such as increased pet ownership, growing disposable income, and the rising willingness of people to spend on their pets' well-being. The veterinary healthcare industry has experienced substantial growth worldwide.
Veterinary vaccines have evolved from an experimental endeavor to a routine and relatively safe practice in veterinary medicine. The primary goals of veterinary vaccines are to enhance the health and welfare of companion animals and to increase the cost-effective production of livestock. The use of veterinary vaccines is on the rise, with a significant impact on both animal health and public health. Vaccination is the most widely used tool in veterinary medicine to prevent and control animal diseases, representing the most cost-effective and sustainable method of managing infectious diseases. The field has seen successful applications of recombinant vaccines, with ongoing developments in rationally designed vaccine innovations to benefit animals, animal owners, and ultimately humans. Vaccination is considered the most effective way of preventing viral diseases in veterinary medicine, with attenuated and inactivated virus vaccines being the mainstay.
Moreover, the increasing expenditure on pet health and veterinary services, along with the growing adoption of pet insurance, is expected to drive the utilization of routine vaccinations. This presents an opportunity for the players operating in the veterinary vaccines market to capitalize on the rising demand for companion animal vaccines.
Rising pet ownership and zoonotic disease concerns are the market drivers for the global veterinary vaccines market. Additionally, the demand for animal-derived protein is expected to double by 2050, raising concerns about sustainability and food security. Economic development and increased urbanization are driving major transitions in population-level dietary patterns, particularly in low and middle-income countries, leading to most of the global increases in demand for animal-origin foods.
The key market restraints for the veterinary vaccines market include effective storage, as vaccines require specific low temperatures to remain effective, and any deviation can lead to significant wastage and financial loss. Cold storage-related spending on vaccines amounts to about 80% of their total cost, and manufacturers and distributors use various equipment and monitoring devices such as refrigerators, thermometers, and cold chain monitors to ensure proper storage. Vaccine storage units need to be carefully selected, regularly maintained, and consistently monitored to maintain the recommended temperature, generating significant costs for manufacturers.
The key market opportunities for the veterinary vaccines market is being driven by the emergence of new diseases and the limitations of conventional live and inactivated vaccines, leading to the introduction of technologically advanced recombinant and DNA vaccines. These new vaccines offer wider immune responses, ease of production, storage, and transportation, rapid development for emerging diseases, and higher stability at a wider range of temperatures, reducing the cost of maintaining the recommended temperature. This advancement is expected to provide growth opportunities for animal vaccine manufacturers, with a focus on developing DNA vaccines for diseases such as H1N1 influenza.
 |
 |
 |
The veterinary vaccines market forecast on the basis of distribution by technology (inactivated vaccines, conjugate vaccines, toxoid vaccines, live attenuated vaccines, recombinant vaccines, subunit and DNA vaccines). On the basis of animal type (companion animal vaccine and livestock animal vaccine). On the basis of route of administration (parenteral, oral and intranasal). On the basis of distribution channel (veterinary hospitals and clinics, pharmacies and mobile veterinary units). By geographical regions, the market is analyzed across North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America.
Technology Analysis Section
Based on technology, the veterinary vaccines market is analyzed across inactivated vaccines, conjugate vaccines, toxoid vaccines, live attenuated vaccines, recombinant vaccines, subunit and DNA vaccines. The dominant segment in the veterinary vaccines market is the attenuated live vaccines, which is the oldest vaccination method used in the veterinary field. This method is also being trialed for the development of additional applications, such as the development of protein subunit vaccines for swine, which are administered intramuscularly. These products aid in reducing the mortality rate and improving the lifespan of disease-affected swine. On the other hand, the recombinant vaccine segment is one of the fastest-growing segments over the forecast period. These vaccine formulations can avoid the need for adjuvants, increase the viability of the vaccine, and improve stability. Some of the recombinant vaccines available for veterinary medicine are vaccines against canine distemper, pseudorabies, Newcastle disease, Lyme disease, and avian influenza.
Based on region, the veterinary vaccines market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America has been the dominant force in the market and is projected to maintain its dominance in the foreseeable future. This can be attributed to several factors, including the high prevalence of livestock and zoonotic diseases leading to large-scale animal deaths, the presence of well-established pharmaceutical firms striving for wide commercialization of their vaccines, and the increasing adoption of vaccination for canine disorders, along with the rising pet population in the U.S. These factors contribute to the expansion of the regional market.
Key market players that are engaged in veterinary vaccines market are (in alphabetical order) Aratana Therapeutics, Bayer, Boehringer Ingelheim, Ceva Santé Animale, Elanco Animal Health, Eli Lilly, Merck, Phibro Animal Health Corporation, Virbac Group and Zoetis. This market report includes an easily searchable excel database of all the veterinary vaccines companies worldwide.
| Aspects | Details | |
| by Technology |
|
|
| by Animal Type |
|
|
| by Route of Administration |
|
|
| by Distribution Channel |
|
|
| Key Geographical Regions |
|
|
| Key Market Players |
|
|
There has been recent activity in the veterinary vaccines industry and some of the key developments have been mentioned below:
In October 2023, Pirbright and VIDO announced the expansion of their collaboration to advance vaccine manufacturing to drive innovations for animal health.